Lilly, Novo bet on amylin obesity drugs after GLP-1s
The next generation of blockbuster obesity drugs isn’t trying to replace GLP-1 medicines. Instead, drugmakers are developing treatments that can complement existing drugs and push weight loss further, or offer new options for potentially millions of people who may not get enough benefit from GLP-1s. That’s the early potential of a new slate of injections,…